Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
- 300 Downloads
Background: Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy. Purpose: The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status. Methods: Progressive radio and chemotherapy naïve low grade glioma patients with O6-methyl-guanine-DNA-methyl-tranferase (MGMT) promoter status evaluation were considered eligible. Chemotherapy cycles consisted of temozolomide 75 mg/m2/daily for 21 days every 28 days for 12 cycles. Results: A total of 30 patients (median age 45 [range: 24.2–68.6] years) with a median KPS of 90 (range 60–90) were accrued. The overall response rate was 30% (9 partial responses); 17 patients (56.7%) had disease stabilization. Conclusion: The prolonged temozolomide schedule considered in the present study is followed by a high response rate; toxicity is acceptable. Further randomized trials should therefore be conducted to confirm the efficacy of this regimen as first-line therapy in patients with progressive low grade glioma.
KeywordsClinical trials Low grade gliomas 1p/19q deletions MGMT Prolonged temozolomide
We are indebted to the Research and Development Unit of Azienda Ospedaliera di Padova for the research funding.
- 1.CBTRUS, C.B.t.r.o.t.U.S. (2004) Primary brain tumors in the United States. Statistical report 1997–2001Google Scholar
- 2.Brandes AA, Tosoni A, Kortmann RD (2003) Guidelines for the management and treatment of low-grade gliomas. Forum (Genova) 13:4–17Google Scholar
- 5.Denis L, Tolcher A, Figueroa et al (2000) Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic—pharmacodynamic study. In ASCO Proceedings, 2000 Annual Meeting, abstract number 786Google Scholar
- 13.Simon R (1989) Designs for efficient clinical trials. Oncology (Huntingt) 3:43–49 discussion 51–43Google Scholar
- 22.Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T (2003) Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13:176–184PubMedGoogle Scholar